There’s so
much more to see

Look closer and you will see the impact BYOOVIZ, a biosimilar* to Lucentis® (ranibizumab injection), may have on the lives of more patients

BYOOVIZ is an FDA-approved biosimilar indicated to treat
nAMD, macular edema following RVO, and mCNV1

FDA=US Food and Drug Administration; mCNV=myopic choroidal neovascularization; nAMD=neovascular age-related macular degeneration; RVO=retinal vein occlusion.

*Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a

reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product.